Detalhe da pesquisa
1.
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Future Oncol;
20(10): 563-578, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38126311
2.
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
Oncologist;
27(7): e589-e596, 2022 07 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35462406
3.
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Cancer;
124(22): 4342-4349, 2018 11 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30395359
4.
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.
J Urol;
200(2): 344-352, 2018 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29630978
5.
Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.
Eur J Haematol;
98(3): 269-279, 2017 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27859769
6.
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Lancet Oncol;
15(11): 1263-8, 2014 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25242048
7.
Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.
Am J Gastroenterol;
109(2): 212-23, 2014 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24394749
8.
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Haematologica;
99(6): 1114-22, 2014 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24763402
9.
To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma.
J Oncol Pharm Pract;
25(4): 1027-1030, 2019 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30786822
10.
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk;
23(5): 385-393, 2023 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36967244
11.
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
Prostate Cancer Prostatic Dis;
26(1): 156-161, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36209239
12.
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
J Comp Eff Res;
12(6): e220186, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37114426
13.
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.
Am J Gastroenterol;
107(9): 1409-22, 2012 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22890223
14.
A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Gynecol Oncol;
126(3): 369-74, 2012 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22659190
15.
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
J Drugs Dermatol;
11(10): 1210-7, 2012 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23134986
16.
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Eur Urol;
81(2): 184-192, 2022 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34916086
17.
Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.
Clin Lung Cancer;
23(7): 571-577, 2022 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36085282
18.
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Clin Drug Investig;
42(1): 29-41, 2022 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34822128
19.
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.
EJHaem;
3(1): 97-108, 2022 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35846215
20.
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
Cancer;
117(16): 3758-62, 2011 Aug 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21328327